SCHEMBL5541579

SCHEMBL5541579

O=[C]OCCc1cccc(SC(F)(F)F)c1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.38
CETP P11597 2/20 0.37
PTPRZ1 P23471 4/20 0.34
PTPN1 P18031 2/20 0.34
HTR2C P28335 1/20 0.33
HTR6 P50406 1/20 0.33
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
PPARG P37231 2/20 0.32
PPARA Q07869 2/20 0.32
RXFP1 Q9HBX9 2/20 0.32
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HTT P42858 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
TRPV1 Q8NER1 2/20 0.30
MIF P14174 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL514240 0.85 FFAR4 (0.44) FFAR4CETPPTPRZ1PTPN1UBE2M
SCHEMBL5541929 0.81 PTPRZ1 (0.47) FFAR4PTPRZ1PTPN1LMNAMAPT
SCHEMBL5545075 0.80 MAPT (0.38) HTR2CHTR6MAPT
SCHEMBL2093846 0.77 TAAR1 (0.56) FFAR4HTR2CTAAR1MIF
SCHEMBL26622054 0.76 CETP (0.40) FFAR4CETPPTPRZ1PTPN1HTR2C
SCHEMBL2090442 0.75 CHRM2 (0.52) CETP
SCHEMBL2095453 0.74 TAAR1 (0.52) TAAR1MIF
SCHEMBL17288832 0.74 FFAR4 (0.39) FFAR4CETPPTPRZ1PTPN1HTR2C
SCHEMBL13064250 0.74 CETP (0.40) FFAR4CETPPTPRZ1PTPN1HTR2C
SCHEMBL3278395 0.74 CETP (0.42) FFAR4CETPPTPRZ1PTPN1HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FFAR4 338/4885CETP 4769/4885PTPRZ1 2595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.